TITLE: Human Papillomavirus Testing for Cervical Cancer Screening: Clinical Effectiveness, Cost-effectiveness and Guidelines

DATE: 06 October 2016

RESEARCH QUESTIONS

1. What is the evidence regarding the clinical effectiveness and safety of human papillomavirus (HPV) testing for primary cervical cancer screening?

2. What is the cost-effectiveness of HPV testing for primary cervical cancer screening?

3. What are the guidelines regarding HPV testing for cervical cancer screening?

KEY FINDINGS

Seven systematic reviews and meta-analyses and two evidence-based guidelines were identified regarding HPV testing for cervical cancer screening.

METHODS

A limited literature search was conducted on key resources including PubMed, The Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. Methodological filters were applied to limit retrieval to health technology assessments, systematic reviews, meta-analyses, and guidelines. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2011 and October 3, 2016. Internet links were provided, where available.

SELECTION CRITERIA

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that the Canadian Agency for Drugs and Technologies in Health (CADTH) could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report.

Copyright: This report contains CADTH copyright material and may contain material in which a third party owns copyright. This report may be used for the purposes of research or private study only. It may not be copied, posted on a website, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner.

Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions.
Table 1: Selection Criteria

<table>
<thead>
<tr>
<th>Population</th>
<th>Adult women who are eligible for cervical cancer screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>Testing for human papillomavirus (HPV)</td>
</tr>
<tr>
<td>Comparator</td>
<td>Conventional cytology</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Clinical effectiveness, safety, test characteristics/accuracy, recommendations for screening</td>
</tr>
<tr>
<td>Study Designs</td>
<td>Health technology assessments, systematic reviews, meta-analyses, evidence-based guidelines</td>
</tr>
</tbody>
</table>

**RESULTS**

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by and evidence-based guidelines.

Seven systematic reviews and meta-analyses and two evidence-based guidelines were identified regarding the clinical effectiveness, safety, and guidelines for HPV testing for cervical cancer screening.

Additional references of potential interest are provided in the appendix.

**Health Technology Assessments**
No literature identified.

**Systematic Reviews and Meta-analyses**


Guidelines and Recommendations


PREPARED BY:
Canadian Agency for Drugs and Technologies in Health
Tel: 1-866-898-8439
www.cadth.ca
APPENDIX – FURTHER INFORMATION:

Previous CADTH Reports


Clinical Practice Guidelines – Methodology Not Specified


Economic Evaluation


Systematic Reviews – Combination Testing


Non-Randomized Studies

Qualitative Studies


Review Articles